Tag: Pml

Infusion reactions are a common side effect of Ocrevus, with 34% to 40% of patients experiencing them in clinical trials. However, a bad reaction to Ocrevus can also involve more severe issues, including life-threatening infections and other serious medical complications.

Up to 85% of the general adult population carries the John Cunningham (JC) virus, which is typically harmless. However, for those on specific immunomodulating drugs, understanding 'What medication can cause PML?' is vital, as these drugs can reactivate the virus, leading to this serious brain disease.

In August 2023, the FDA approved Tyruko, the first biosimilar for Tysabri, signaling a major shift in multiple sclerosis (MS) treatment. As medical understanding evolves, patients and healthcare providers are considering new therapeutic options and weigh the risks and benefits of continuing or discontinuing older medications like Tysabri, which carries the risk of the brain infection PML.

According to the MS Trust, both Ocrevus and Tysabri, while highly effective for treating multiple sclerosis (MS), carry specific safety risks, including the rare but serious Progressive Multifocal Leukoencephalopathy (PML). The question of 'Is ocrevus safer than Tysabri?' is nuanced, depending heavily on a patient's individual health profile and risk factors.

While Tysabri has been a highly effective treatment for relapsing multiple sclerosis for many years, offering a 67% reduction in relapse rates compared to placebo in a 2-year clinical trial, its association with the risk of a serious brain infection (PML) has prompted many patients and neurologists to consider **what is better than Tysabri**. The answer is not a single medication, but rather a personalized evaluation of several factors to determine the best alternative for each individual.

In 2005, just months after its accelerated approval, the manufacturers of the promising multiple sclerosis drug Tysabri (natalizumab) voluntarily withdrew it from the market following the discovery of a rare but fatal brain infection. This decision was in direct response to why was Tysabri taken off the market and fundamentally reshaped drug development and safety protocols for high-efficacy treatments.

Tysabri (natalizumab) carries a U.S. Food and Drug Administration (FDA) boxed warning due to the increased risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection is a primary concern for patients, making it critical to understand **who should not take Tysabri** to ensure safety and effectiveness.

Up to 84% of multiple sclerosis (MS) patients report fatigue as a significant symptom [1.2.2]. This raises a critical question for those on disease-modifying therapies: Does Tysabri give you energy or contribute to the fatigue it's meant to help manage?

Progressive Multifocal Leukoencephalopathy (PML) is a rare but serious brain infection caused by the reactivation of the John Cunningham (JC) virus [1.10.2]. This article explores a critical question for many patients: **what drugs increase the risk of PML?**

Many people carry the John Cunningham (JC) virus, which, in those with weakened immune systems, can lead to a rare but serious brain infection called Progressive Multifocal Leukoencephalopathy (PML). For individuals with multiple sclerosis (MS) who test positive for the virus, a key question is whether they can take Kesimpta if they are JCV positive.